Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer
Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer
复制标题
DOI：
10.1016/s0022-5347(05)67114-5
复制
发表时间：
2000-11-01
影响因子：
6.6
通讯作者：
Disis, ML
中科院分区：
文献类型：
--
作者：
McNeel, DG;Nguyen, LD;Disis, ML
目的：目前，几种靶向前列腺癌相关蛋白的免疫疗法正在进行临床研究。然而，一般来说，对前列腺癌的免疫原性或哪些前列腺癌相关蛋白引起免疫应答知之甚少。我们确定前列腺癌患者是否对已知的前列腺癌相关蛋白具有抗体免疫力，这种免疫力的普遍性是什么，以及对单个蛋白的免疫力是否与疾病的阶段相关。材料和方法：我们评估了针对前列腺特异性抗原（PSA）、前列腺酸性磷酸酶、p53和HER-2/neu（所有已知的前列腺癌相关蛋白）的固有体液免疫应答，结果：PSA抗体免疫在患者（11%，22/200）和对照人群（1.5%，3/100，p = 0.02）之间有显著差异，并且1：100或更高滴度在雄激素非依赖性疾病患者亚组（11%，6/56）中特别普遍。检测到前列腺酸性磷酸酶和p53抗体免疫（5.5%，11/200和6%，12/200），与对照人群（4%，4/100，p = 0.57和7%，7/100，p = 0.74）没有差异。HER-2/neu抗体免疫显着较高的前列腺癌患者（15.5%，31 200）相比，对照组（2%，2 100，p = 0.0004），和滴度1：100或更高的雄激素非依赖性疾病的患者亚组（16%，9 56）。结论：这些研究结果表明，前列腺癌是一种免疫原性肿瘤。此外，对于PSA和HER-2/neu，雄激素非依赖性疾病患者的抗体免疫率较高，表明即使是晚期前列腺癌患者也可以对其肿瘤产生免疫应答。
Purpose: Several immune based therapies targeting prostate cancer associated proteins are currently undergoing clinical investigation. In general, however, little is known about the immunogenicity of prostate cancer or which prostate cancer associated proteins elicit immune responses. We determine whether patients with prostate cancer have antibody immunity to known prostate cancer associated proteins, what the prevalence of this immunity is and whether immunity to individual proteins is associated with the stage of disease.Materials and Methods: We evaluated the inherent humoral immune response against prostate specific antigen (PSA), prostatic acid phosphatase, p53 and HER-2/neu, all known prostate cancer associated proteins, in 200 patients with various stages of disease and male controls.Results: Antibody immunity to PSA was significantly different between the patient (11%, 22 of 200) and control populations (1.5%, 3 of 100, p = 0.02), and titers 1:100 or greater were particularly prevalent in the subgroup of patients with androgen independent disease (11%, 6 of 56). Antibody immunity to prostatic acid phosphatase and p53 was detected (5.5%, 11 of 200 and 6%, 12 of 200), and was not different from the control population (4%, 4 of 100, p = 0.57 and 7%, 7 of 100, p = 0.74). Antibody immunity to HER-2/neu was significantly higher in patients with prostate cancer (15.5%, 31 of 200) compared to controls (2%, 2 of 100, p = 0.0004), and titers 1:100 or greater were most prevalent in the subgroup of patients with androgen independent disease (16%, 9 of 56).Conclusions: These findings suggest that prostate cancer is an immunogenic tumor. Moreover, for PSA and HER-2/neu the prevalence of antibody immunity was higher in patients with androgen independent disease, indicating that even patients with advanced stage prostate cancer can have an immune response to their tumor.